Wednesday, November 29, 2006 6:00:00 AM PDT | VentureDeal Staff
CHELMSFORD, MA -- Magellan Biosciences announced the closing of a $50 million round of new debt and equity financing. Funds will be used to expand product development and strategic acquisitions. The company develops products for clinical diagnostics, hospital-based labs and near-patient testing and serves markets worldwide. Abingworth Management led the round, which included seven previous and new investors.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
